Shattuck Labs

IPO

Advancing DR3-targeting therapies for IBD and beyond.

Public · Austin, United States · Founded 2016 · $221.0M raised

Headquarters
Austin, Texas
Employees
51–200
Founded
2016
Business Model
B2B
Total Funding
$221.0M
Last Round
$118.0M Series BAug 2025
Rounds
2
Type
Public

About

Shattuck Labs (NASDAQ: STTK) is a clinical-stage biotechnology company developing novel DR3-targeting biologic therapies for inflammatory and immune-mediated diseases. Its lead program, SL-325, is a potentially first-in-class DR3 blocking antibody in Phase 1 development for inflammatory bowel disease. Founded in 2016 and headquartered in Austin, Texas.

Summary

Shattuck Labs is a Biotech company based in Austin, United States, founded in 2016. It has raised $221.0M in total across 2 rounds, most recently a $118.0M Series B round in Aug 2025. Investors include Redmile Group, OrbiMed and Janus Henderson Investors.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Corporate RoundCorporate RoundAug 2025
$103.0M

Sign up to see all 3 rounds

Series B through Corporate Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Shattuck Labs on Indexed.vc
<a href="https://indexed.vc/companies/shattuck-labs"><img src="https://indexed.vc/api/badge/company/shattuck-labs" alt="Shattuck Labs on Indexed.vc" width="260" height="76" /></a>